Linear energy transfer (LET)
A measure of how densely a particle of radiation deposits its energy as it travels through tissue. Alpha particles dump their energy in a short, dense burst; beta particles and gamma rays spread it thinly over a much longer track.
Overview
Linear energy transfer (L or LET) is the average energy that a charged ionising particle transfers to the medium per unit length of its track, L = dE/dl, expressed in keV per micrometre (keV/µm). It describes the spatial density of energy deposition (and therefore of ionisation events) along a particle's path, which is what ultimately determines the biological severity of the damage caused for a given absorbed dose.
Representative values illustrate the range: cobalt-60 gamma rays and diagnostic x-rays are low-LET (roughly 0.2-2 keV/µm), beta particles from radionuclides such as lutetium-177 are also low-LET (a 1 MeV beta particle deposits roughly 0.2 keV/µm and travels several millimetres), while alpha particles are high-LET, depositing on the order of 80-150 keV/µm over a track of only tens to about a hundred micrometres (a handful of cell diameters). High-LET radiation causes densely clustered ionisations that produce more complex, harder-to-repair DNA double-strand breaks than the sparse ionisation from low-LET beta or gamma radiation, which is the physical basis for targeted alpha therapy's distinct toxicity and efficacy profile compared with beta-emitting radioligand therapy.
LET is the mechanistic quantity underlying both the regulatory radiation weighting factor used in equivalent dose (wR = 20 for alpha versus 1 for beta/gamma) and the empirically measured relative biological effectiveness used to compare therapeutic effect between alpha- and beta-emitting radiopharmaceuticals.
- PSMA / SSTR-positive cell
Showing the technology this term belongs to: Targeted alpha therapy.
Similar pages
not linked directly; found by shared links- TermBecquerel and curie (units of radioactivity)
Shares Absorbed dose and the gray (Gy), Radioligand therapy (beta emitters), Lutetium-177.
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares Alpha vs beta emitters, Targeted alpha therapy, Radioligand therapy (beta emitters), Lutetium-177.
- CompanyAlpha-9 Oncology
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Lutetium-177.
- CompanyARTBIO
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Lutetium-177.
- InstitutionOslo University Hospital, The Norwegian Radium Hospital
Shares Alpha vs beta emitters, Targeted alpha therapy, Radioligand therapy (beta emitters).
- PairingBeta radioligand → alpha radioligand
Shares Alpha vs beta emitters, Targeted alpha therapy, Radioligand therapy (beta emitters), Lutetium-177.
- TechnologyIn vivo dosimetry and patient-specific quality assurance
Shares Equivalent dose and effective dose (sievert), Absorbed dose and the gray (Gy).
- PairingBeta PRRT → alpha PRRT
Shares Alpha vs beta emitters, Targeted alpha therapy, Lutetium-177.